After finishing at $16.27 in the prior trading day, Neogenomics Inc. (NASDAQ: NEO) closed at $16.13, down -0.86%. On the day, 857849 shares were traded. NEO stock price reached its highest trading level at $16.63 during the session, while it also had its lowest trading level at $16.01.
Ratios:
Our goal is to gain a better understanding of NEO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.95 and its Current Ratio is at 6.20. In the meantime, Its Debt-to-Equity ratio is 0.65 whereas as Long-Term Debt/Eq ratio is at 0.64.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, BTIG Research on December 29, 2023, Reiterated its Buy rating but revised its target price to $21 from $25 previously.
On August 21, 2023, Stephens Upgraded its rating to Overweight which previously was Equal-Weight but kept the price unchanged to $18.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 15 when Olivo Alicia C sold 2,587 shares for $14.96 per share. The transaction valued at 38,713 led to the insider holds 34,866 shares of the business.
Olivo Alicia C sold 2,669 shares of NEO for $49,083 on Nov 17. The General Counsel now owns 37,140 shares after completing the transaction at $18.39 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NEO now has a Market Capitalization of 2.06B and an Enterprise Value of 2.25B. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.48 while its Price-to-Book (P/B) ratio in mrq is 2.18. Its current Enterprise Value per Revenue stands at 3.81 whereas that against EBITDA is -128.06.
Stock Price History:
Over the past 52 weeks, NEO has reached a high of $21.22, while it has fallen to a 52-week low of $11.03. The 50-Day Moving Average of the stock is 16.37, while the 200-Day Moving Average is calculated to be 15.89.
Shares Statistics:
The stock has traded on average 1.14M shares per day over the past 3-months and 1.53M shares per day over the last 10 days, according to various share statistics. A total of 127.37M shares are outstanding, with a floating share count of 126.08M. Insiders hold about 1.20% of the company’s shares, while institutions hold 99.25% stake in the company. Shares short for NEO as of Jan 31, 2024 were 7.77M with a Short Ratio of 6.84, compared to 9.29M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 6.10% and a Short% of Float of 8.61%.
Earnings Estimates
Its stock is currently analyzed by 11 different market analysts. On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of -$0.02 and a low estimate of -$0.11, while EPS last year was -$0.09. The consensus estimate for the next quarter is -$0.01, with high estimates of $0.01 and low estimates of -$0.06.
Analysts are recommending an EPS of between $0.08 and -$0.19 for the fiscal current year, implying an average EPS of -$0.01. EPS for the following year is $0.13, with 12 analysts recommending between $0.2 and $0.01.
Revenue Estimates
12 analysts predict $149.39M in revenue for the current quarter. It ranges from a high estimate of $151.1M to a low estimate of $146M. As of the current estimate, Neogenomics Inc.’s year-ago sales were $137.22M, an estimated increase of 8.90% from the year-ago figure. For the next quarter, 12 analysts are estimating revenue of $162.12M, an increase of 18.00% over than the figure of $8.90% in the same quarter last year. There is a high estimate of $164.22M for the next quarter, whereas the lowest estimate is $156.3M.
A total of 13 analysts have provided revenue estimates for NEO’s current fiscal year. The highest revenue estimate was $659M, while the lowest revenue estimate was $625.2M, resulting in an average revenue estimate of $652.45M. In the same quarter a year ago, actual revenue was $591.64M, up 10.30% from the average estimate. Based on 12 analysts’ estimates, the company’s revenue will be $715.97M in the next fiscal year. The high estimate is $727.08M and the low estimate is $683.6M. The average revenue growth estimate for next year is up 9.70% from the average revenue estimate for this year.
